We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis (MF) using reduced-intensity conditioning (RIC). The median age at RIC HCT was 55 yr. Donors were a matched sibling donor (MSD) in 34% of RIC HO's, an HLA well-matched unrelated donor CURD) in 45%, and a partially matched/mismatched URD in 21%. Risk stratification according to the Dynamic International Prognostic Scoring System (DIPSS) was 12% low, 49% intermediate-1, 37% intermediate-2, and 1% high. The probability of survival at 5 yr was 47% (95% confidence interval [CI], 40% to 53%). In a multivariate analysis, donor type was the sole independent factor associated with survival. ...
We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity c...
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (...
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small...
We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hemato...
International audienceWe evaluated outcomes and associated prognostic factors in 233 patients underg...
AbstractWe evaluated outcomes and associated prognostic factors in 233 patients undergoing allogenei...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the o...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the o...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the o...
AbstractThis report describes our experience with reduced intensity conditioning (RIC) allogeneic he...
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small...
Background: Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for myelo...
Background Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for myelof...
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (...
International audienceAllogeneic haematopoietic stem-cell transplantation (HSCT) is the only curativ...
We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity c...
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (...
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small...
We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hemato...
International audienceWe evaluated outcomes and associated prognostic factors in 233 patients underg...
AbstractWe evaluated outcomes and associated prognostic factors in 233 patients undergoing allogenei...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the o...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the o...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed the o...
AbstractThis report describes our experience with reduced intensity conditioning (RIC) allogeneic he...
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small...
Background: Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for myelo...
Background Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for myelof...
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (...
International audienceAllogeneic haematopoietic stem-cell transplantation (HSCT) is the only curativ...
We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity c...
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (...
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small...